Oncternal Therapeutics company info

What does Oncternal Therapeutics do?
Oncternal Therapeutics (NASDAQ:ONCT) is a biopharmaceutical company dedicated to developing innovative therapies for cancer treatment with a focus on addressing unmet medical needs. With an aim to extend and enhance the lives of patients suffering from cancer, Oncternal is currently engaging in several promising projects, including the development of targeted therapies that leverage the latest advancements in oncology research. The company's pipeline showcases a diverse range of investigational drugs, each designed to target specific mechanisms involved in the growth and spread of cancerous cells. Objectives at Oncternal include progressing clinical trials to eventually bring new, effective cancer treatments to market, improving patient outcomes, and establishing partnerships to enhance research and development capabilities.
Oncternal Therapeutics company media
Company Snapshot

Is Oncternal Therapeutics a public or private company?

key
Ownership
Public

How many people does Oncternal Therapeutics employ?

people
Employees
29

What sector is Oncternal Therapeutics in?

pie chart
Sector
Health Care

Where is the head office for Oncternal Therapeutics?

location pin
Head Office
San Diego, United States

What year was Oncternal Therapeutics founded?

founded flag
Year Founded
1997
What does Oncternal Therapeutics specialise in?
/Cancer Treatments /Clinical Stage /TK216 Medicine /ROR1 Antibody /Biopharmaceutical Research /Drug Development

What are the products and/or services of Oncternal Therapeutics?

Overview of Oncternal Therapeutics offerings
Cirmtuzumab, a ROR1 monoclonal antibody targeting chronic lymphocytic leukemia, mantle cell lymphoma, and breast cancer.
TK216, a small molecule ETS-family transcription factor inhibitor for Ewing sarcoma.
ROR1 CAR-T therapies, focusing on innovative chimeric antigen receptor T-cell therapies for solid tumors and hematologic cancers.
Zilovertamab vedotin, an antibody-drug conjugate targeting ROR1-expressing tumors.
ONCT-216, targeting B-cell malignancies and certain solid tumors with a focus on developing next-generation inhibitors.
Collaborative research to identify and advance novel cancer therapeutic candidates, emphasizing partnerships with academia and industry.

Who is in the executive team of Oncternal Therapeutics?

Oncternal Therapeutics leadership team
  • Dr. James B. Breitmeyer M.D., Ph.D.
    Dr. James B. Breitmeyer M.D., Ph.D.
    President, CEO & Director
  • Dr. Salim  Yazji M.D.
    Dr. Salim Yazji M.D.
    Chief Medical Officer
  • Mr. Richard G. Vincent CPA
    Mr. Richard G. Vincent CPA
    CFO & Treasurer
  • Dr. Rajesh  Krishnan Ph.D.
    Dr. Rajesh Krishnan Ph.D.
    Chief Technical & Scientific Officer
  • Mr. Chase C. Leavitt
    Mr. Chase C. Leavitt
    General Counsel & Secretary
  • Mr. Pablo  Urbaneja
    Mr. Pablo Urbaneja
    Senior Vice President of Corporate Development
  • Anita  Wiseth
    Anita Wiseth
    Senior Vice President of Human Resources